Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2009

01-11-2009 | Research Article

Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma

Authors: David M. Schuster, Jonathon A. Nye, Peter T. Nieh, John R. Votaw, Raghuveer K. Halkar, Muta M. Issa, Weiping Yu, Julio Sepulveda, Wanzhen Zeng, Andrew Young, Mark M. Goodman

Published in: Molecular Imaging and Biology | Issue 6/2009

Login to get access

Abstract

Purpose

Assessment of renal masses with conventional imaging may be challenging. Anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) is a synthetic l-leucine analog with relatively little renal excretion. The present study examines anti-[18F]FACBC positron emission tomography uptake in patients with renal masses.

Procedures

Six patients with seven renal lesions were imaged dynamically for 2 h after injection of 10–10.9 mCi (370–403 MBq) anti-[18F]FACBC. Lesions were evaluated qualitatively and quantitatively and correlated with histology.

Results

Four clear cell and one Rosai–Dorfman lesion were hypo/isointense to normal cortex; two papillary lesions in the same patient were hyperintense. Mean SUVmax ± SD at 30 min was 2.8 ± 0.24 for clear cell carcinomas and 4.5 ± 1.7 for papillary cell lesions. Mean SUVmax/SUVmean ratios ± SD of lesion to normal cortex at 30 min was 1.15 ± 0.19 for the clear cell carcinomas and 2.3 ± 0.84 for papillary cell.

Conclusions

In this small patient sample, relative amino acid transport compared with renal cortex is elevated in renal papillary cell carcinoma but not in clear cell carcinoma.
Literature
1.
2.
Rodriguez R, Fishman EK, Marshall FF (1995) Differential diagnosis and evaluation of the incidentally discovered renal mass. Semin Urol Oncol 13:246–253PubMed
3.
Montie JE (1991) The incidental renal mass. Management alternatives. Urol Clin North Am 18:427–436PubMed
4.
Davidson AJ, Hartman DS, Choyke PL, Wagner BJ (1997) Radiologic assessment of renal masses: implications for patient care. Radiology 202:297–305PubMed
5.
Kutikov A, Fossett LK, Ramchandani P et al (2006) Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 68:737–740CrossRefPubMed
6.
Bolton DM, Wong P, Lawrentschuk N (2007) Renal cell carcinoma: imaging and therapy. Curr Opin Urol 17:337–340CrossRefPubMed
7.
Zhang J, Lefkowitz RA, Ishill NM et al (2007) Solid renal cortical tumors: differentiation with CT. Radiology 244:494–504CrossRefPubMed
8.
Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806–1809CrossRefPubMed
9.
Schuster DM, Votaw JR, Nieh PT et al (2007) Initial Experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48:56–63PubMed
10.
Martarello L, McConathy J, Camp VM et al (2002) Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection. J Med Chem 45:2250–2259CrossRefPubMed
11.
McConathy J, Martarello L, Simpson NE et al (2002) Uptake profiles of six 18F-labeled amino acids for tumor imaging: comparison of in vitro and in vivo uptake of branched chain and cyclobutyl amino acids by 9LGliosarcoma tumor cells. J Nucl Med 43:41P
12.
McConathy J, Voll RJ, Yu W, Crowe RJ, Goodman MM (2003) Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot 58:657–666CrossRefPubMed
13.
Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 48:1017–1020CrossRefPubMed
14.
Oka S, Hattori R, Kurosaki F et al (2007) A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 48:46–55PubMed
15.
Schuster DM, Votaw JR, Halkar RK et al (2003) Uptake of the synthetic PET amino acid radiotracer 1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (18F-FACBC) within primary and metastic brain cancer compared with 18F-fluorodeoxyglucose (18F-FDG). J Nucl Med 5:167
16.
Shoup TM, Olson J, Hoffman JM et al (1999) Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 40:331–338PubMed
17.
Ruppert-Kohlmayr AJ, Uggowitzer M, Meissnitzer T, Ruppert G (2004) Differentiation of renal clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement parameters. AJR Am J Roentgenol 183:1387–1391PubMed
Metadata
Title
Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma
Authors
David M. Schuster
Jonathon A. Nye
Peter T. Nieh
John R. Votaw
Raghuveer K. Halkar
Muta M. Issa
Weiping Yu
Julio Sepulveda
Wanzhen Zeng
Andrew Young
Mark M. Goodman
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 6/2009
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-009-0220-5

Other articles of this Issue 6/2009

Molecular Imaging and Biology 6/2009 Go to the issue

Research Article

NEC Density and Liver ROI S/N Ratio for Image Quality Control of Whole-Body FDG-PET Scans: Comparison with Visual Assessment

Research Article

FDG-Accumulating Atherosclerotic Plaques Identified with 18F-FDG-PET/CT in 141 Patients

Response to Letter to the Editor

Letter to the Editor

Research Article

Targeting Gelatinases with a Near-Infrared Fluorescent Cyclic His-Try-Gly-Phe Peptide

Research Article

[11C]-DPA-713 and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis

Research Article

Imaging Correlates of Differential Expression of Indoleamine 2,3-Dioxygenase in Human Brain Tumors